Menu
1 min read · estimated
APPROVED USE
What FDA approved
Children age 1 and older and young adults with ALK-positive systemic anaplastic large cell lymphoma that relapsed or resisted treatment.
LAMPGEN ANALYSIS
Why it matters
The decision extends an ALK inhibitor from lung cancer into a distinct pediatric and young adult lymphoma population.
What research teams should watch
Confirm ALK status, systemic disease, age and prior treatment response at screening.
PRIMARY RECORDS